Wilms’ tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability

Abstract

BackgroundWilms’ tumor 1-associating protein (WTAP) plays an important role in physiological processes and the development of tumor such as cell cycle regulation. The regulation of cell cycle is mainly dependent on cyclins and cyclin-dependent protein kinases (CDKs). Recent studies have shown that CDKs are closely related to the tumor diagnosis, progression and response to treatment. However, their specific biological roles and related mechanism in renal cell carcinoma (RCC) remain unknown.MethodsQuantitative real-time PCR, western blotting and immunohistochemistry were used to detect the expression of WTAP and CDK2. The survival analysis was adopted to explore the association between WTAP expression and the prognosis of RCC. Cells were stably transfected with lentivirus approach and cell proliferation and cell cycle, as well as tumorigenesis in nude mice were performed to assess the effect of WTAP in RCC. RNA immunoprecipitation, Luciferase reporter assay and siRNA were employed to identify the direct binding sites of WTAP with CDK2 transcript. Colony formation assay was conducted to confirm the function of CDK2 in WTAP-induced growth promoting.ResultsIn RCC cell lines and tissues, WTAP was significantly over-expressed. Compared with patients with low expression of WTAP, patients with high expression of WTAP had lower overall survival rate. Additionally, cell function test indicated that cell proliferation abilities in WTAP over-expressed group were enhanced, while WTAP knockdown showed the opposite results. Subcutaneous xenograft tumor model displayed that knockdown of WTAP could impede tumorigenesis in vivo. Mechanism study exhibited that CDK2 expression was positively associated with the expression of WTAP. Moreover, WTAP stabilized CDK2 transcript to enhance CDK2 expression via binding to 3′-UTR of CDK2 transcript. Additionally, specific inhibitors of CDK2 activity and small interfering RNA (siRNA) of CDK2 expression inhibited WTAP-mediated promotion of proliferation.ConclusionsThese findings suggest that WTAP may have an oncogenic role in RCC through physically binding to CDK2 transcript and enhancing its transcript stability which might provide new insights into RCC therapy.Electronic supplementary materialThe online version of this article (10.1186/s13046-018-0706-6) contains supplementary material, which is available to authorized users.

High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour‐associated T lymphocyte infiltration

“…Through enrichment analysis, these genes were found to up‐regulate the methylation of mRNA. Studies have found that m6A RNA modifications can affect tumour proliferation and patient prognosis through immunoregulatory effects . Our study also found that T regulatory cells (Treg) and CD4 memory‐activated T cells in patients with high WTAP expression were significantly lower than those in patients with low WTAP expression.…”

Identification of a m6A RNA methylation regulators-based signature for predicting the prognosis of esophageal adenocarcinoma

“…Considering the opposite effect of ALKBH5 in different types of malignant tumors, more preclinical and clinical evidences are required to nd out the exact role of ALKBH5 in EAC. HNRNPA2B1, KIAA1429, WTAP, METTL16 were identi ed as protective genes, which was consistent with the results in many studies [44][45][46][47]. At present, the prognosis assessment mainly relies on TNM stage which includes limited risk factors [2].…”

N6-Methyladenosine: A Novel RNA Imprint in Human Cancer

“…In renal cell carcinoma, WTAP indicates poor survival of patients, and knockdown of WTAP impedes cell proliferation in vitro and tumorigenesis in vivo (56). Mechanistically, WTAP binds to 3 ′ -UTR of cyclin-dependent protein kinase 2 (CDK2) mRNAs and stabilizes the transcripts, lifting CDK2 protein level.…”